Core Viewpoint - Junshi Biosciences (688180) reported a revenue of 2.498 billion yuan for 2025, marking a year-on-year increase of 28.23%, while the net profit attributable to shareholders was a loss of 874 million yuan, an improvement from a loss of 1.281 billion yuan in the previous year [2] Financial Performance - The company achieved a revenue of 2.498 billion yuan, reflecting a growth of 28.23% year-on-year [2] - The net profit attributable to shareholders was a loss of 874 million yuan, compared to a loss of 1.281 billion yuan in the same period last year [2] - The non-recurring net profit was a loss of 989 million yuan, an improvement from a loss of 1.29 billion yuan in the previous year [2] - The basic earnings per share were -0.87 yuan, with a weighted average return on equity of -14.7% [2][6] - The price-to-book ratio (LF) was approximately 5.62 times, and the price-to-sales ratio (TTM) was about 14.06 times [2] Product Performance - The core product, Toripalimab injection (brand name: Tuoyi®), saw a significant sales revenue increase of approximately 37.72% in the domestic market [5] - As of the announcement date, Tuoyi® has been included in the national medical insurance catalog for all 12 approved indications in mainland China, being the only anti-PD-1 monoclonal antibody for the treatment of renal cancer, triple-negative breast cancer, and melanoma [5] - The company is expanding its global commercialization network, with Toripalimab approved for sale in over 40 countries and regions, including mainland China, Hong Kong, the United States, the European Union, India, the United Kingdom, Australia, and Singapore [5]

报告期内，公司营业收入较上年同期增长，主要系公司核心产品特瑞普利单抗注射液(商品名：拓益®) 于国内市场销售收入同比大幅增长。 智通财经APP讯，君实生物(01877)公布2025年业绩快报，营业总收入约24.98亿元，同比增长28.23%;归 属于母公司所有者的净亏损约8.74亿元，同比收窄31.74%;基本每股亏损0.87元。 亏损减少主要系公司 2025 年实施股票期权激励计划，股份支付费用增加，但公司积极落实"提质增效重 回报"行动方案，持续加强各项费用管控，坚持研发管线聚焦、高效投入，降低单位生产成本，提升销 售效率，亏损金额较同期减少。 ...

北京商报讯（记者 王寅浩 宋雨盈）2月27日，君实生物发布2025年业绩快报，2025年度实现营业总收入 24.98亿元，同比增长28.23%；归属于母公司所有者的净亏损为8.74亿元，上年同期为亏损12.81亿元。 业绩快报显示，报告期内，公司营业收入较上年同期增长，主要系核心产品特瑞普利单抗注射液（商品 名：拓益®）于国内市场销售收入同比大幅增长。 ...

Core Viewpoint - Junshi Biosciences (01877) is expected to achieve significant revenue growth and a reduction in net losses by 2025, driven by improved commercialization capabilities and cost control measures [1][2]. Group 1: Financial Projections - The company anticipates a revenue of approximately 2.5 billion yuan for the year 2025, representing a year-on-year growth of about 28.32% [1]. - Research and development expenses are projected to be around 1.353 billion yuan in 2025, reflecting a year-on-year increase of approximately 6.10% [1]. - The expected net loss attributable to shareholders for 2025 is around 873 million yuan, which is a reduction of about 31.85% compared to the previous year [1]. - After excluding the impact of share-based payments, the net loss is projected to be approximately 799 million yuan, indicating a decrease of about 37.62% year-on-year [1]. - The net loss attributable to shareholders, after excluding non-recurring gains and losses, is expected to be around 985 million yuan, a reduction of approximately 23.64% compared to the previous year [1]. Group 2: Product Performance - The company's revenue growth during the reporting period is primarily attributed to increased sales of commercialized drugs [2]. - The core product, Toripalimab injection (brand name: Tuoyi®), has seen a significant year-on-year increase in sales revenue in the domestic market [2]. - As of the announcement date, Tuoyi® has been included in the national medical insurance catalog for all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody in the catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [2].

Core Viewpoint - Junshi Biosciences expects to achieve an annual revenue of approximately 2.5 billion yuan in 2025, representing a year-on-year growth of about 28.32% [1] Revenue and Profit Forecast - The projected R&D expenses are estimated at 1.353 billion yuan, an increase of approximately 6.10% compared to the previous year [1] - The expected net profit attributable to shareholders is a loss of approximately 873 million yuan, which is a reduction in losses compared to the previous year [1] - After excluding the impact of share-based payments, the expected net profit attributable to shareholders is a loss of about 799 million yuan, reflecting a year-on-year decrease in losses of approximately 37.62% [1] - The expected net profit attributable to shareholders, after excluding non-recurring gains and losses, is a loss of about 985 million yuan, which is a reduction in losses of approximately 23.64% [1] Revenue Growth Drivers - The growth in revenue is primarily attributed to the significant increase in sales of the core product, Toripalimab injection (Tuoyi®), in the domestic market [1] - Tuoyi® has been approved for 12 indications, all of which are included in the national medical insurance catalog, and has been approved for sale in multiple countries and regions globally [1] Cost Management and Future Plans - Despite the continued net loss, the company has significantly narrowed the loss amount, mainly due to ongoing efforts in quality improvement and cost control [1] - The company plans to accelerate the clinical trials of several innovative drugs that have competitive advantages in international markets [1]

Core Insights - The company, Junshi Biosciences (688180.SH), expects to achieve an annual revenue of approximately 2.5 billion yuan in 2025, representing a year-on-year increase of about 28.32% [1] - The projected R&D expenses for 2025 are around 1.353 billion yuan, reflecting a growth of 6.10% compared to the previous year [1] - The net profit attributable to the parent company is expected to be a loss of approximately 873 million yuan, which is a reduction in loss of 31.85% year-on-year [1] Revenue and Profitability - The company anticipates a net profit of approximately -795 million yuan after excluding share-based payment impacts, which indicates a year-on-year loss reduction of 37.62% [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be around -985 million yuan, showing a decrease in loss of 23.64% compared to the previous year [2] - The sales revenue growth is primarily driven by the commercialization of pharmaceutical products, particularly the core product, Toripalimab injection (brand name: Tuoyi®), which has seen significant sales growth in the domestic market [2] Product and Market Expansion - As of the announcement date, Tuoyi® has been included in the national medical insurance directory for all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the directory [2] - The company is actively expanding its global commercialization network, with Toripalimab approved for sale in over 40 countries and regions, including mainland China, Hong Kong, the United States, the European Union, India, the United Kingdom, and several others [2]

Core Insights - The company, Junshi Biosciences (688180.SH), expects to achieve an annual revenue of approximately 2.5 billion yuan in 2025, representing a year-on-year increase of about 28.32% [1] - The projected R&D expenses for 2025 are around 1.353 billion yuan, reflecting a growth of 6.10% compared to the previous year [1] - The company anticipates a net loss attributable to shareholders of approximately 873 million yuan for 2025, which is a reduction of 31.85% from the previous year's loss [1] Revenue and Profitability - The expected revenue growth is primarily driven by increased sales of commercialized drugs, particularly the core product, Toripalimab injection (brand name: Tuoyi®) [2] - The net loss, after excluding share-based payment impacts, is projected to be around 799 million yuan, indicating a significant reduction of 37.62% year-on-year [1] Product Performance - Toripalimab injection has seen substantial sales growth in the domestic market, with all 12 approved indications included in the national medical insurance catalog [2] - The product is the only anti-PD-1 monoclonal antibody listed for the treatment of renal cancer, triple-negative breast cancer, and melanoma in the catalog [2] - The company is expanding its global commercialization network, with Toripalimab approved for sale in over 40 countries and regions, including the U.S., EU, and several Asian countries [2]

Core Viewpoint - Junshi Biosciences (01877) expects to achieve approximately 2.5 billion yuan in revenue for the year 2025, representing a year-on-year growth of about 28.32% [1] Financial Performance - The projected R&D expenses for 2025 are approximately 1.353 billion yuan, reflecting a year-on-year increase of about 6.10% [1] - The expected net loss attributable to the parent company for 2025 is around 873 million yuan, a reduction of approximately 31.85% compared to the previous year [1] - After excluding the impact of share-based payments, the net loss is projected to be about 799 million yuan, a decrease of approximately 37.62% year-on-year [1] - The net loss after excluding non-recurring gains and losses is expected to be around 985 million yuan, down about 23.64% year-on-year [1] - The net loss after excluding both share-based payments and non-recurring items is projected to be approximately 911 million yuan, a reduction of about 29.37% year-on-year [1] Product and Market Development - The increase in revenue is primarily due to the growth in sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi®), which saw significant sales growth in the domestic market [1] - As of the announcement date, Tuoyi® has been approved for 12 indications in mainland China, all of which are included in the national medical insurance catalog, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the catalog [1] - The company continues to expand its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, the EU, India, the UK, Jordan, Australia, Singapore, the UAE, Kuwait, Pakistan, Canada, and Bahrain [2] Strategic Initiatives - Despite the expected net loss, the company has significantly narrowed its loss compared to the previous year, mainly due to the implementation of the "quality improvement and efficiency enhancement" action plan, which has improved commercialization capabilities while strengthening cost control and resource focus [2] - The company is advancing its core pipeline efficiently while controlling expenses, rapidly progressing clinical trials for several innovative drugs with international market competitiveness, including JS207 (PD-1/VEGF dual antibody), JS212 (EGFR/HER3 ADC), and JS213 (PD-1/IL-2 fusion protein) [2] - JS207 is currently in Phase II clinical trials, exploring combinations with chemotherapy, monoclonal antibodies, ADCs, and other drugs across multiple tumor types, with ongoing Phase II trials for the combination of JS207 and JS212 [2] - The company aims to accelerate pipeline development and push more advantageous products and indications into the registration clinical trial phase as soon as possible [2]

Core Viewpoint - Junshi Biosciences (01877) has seen a stock price increase of over 3%, currently at 24.28 HKD, following the announcement of new indications for its products being included in the National Medical Insurance Directory for 2025 [1] Group 1: Product Developments - The product Toripalimab injection (brand name: Tuoyi®, product code: JS001) has received two new indications [1] - The product Engreztinib injection (brand name: Junshida®, product code: JS002) has successfully been included in the National Medical Insurance Directory [1] - Both products will be officially included in the updated National Medical Insurance Directory effective January 1, 2026 [1] Group 2: Market Position - As of the announcement date, four commercialized products, including Tuoyi®, have been included in the National Medical Insurance Directory [1] - Tuoyi® is the only anti-PD-1 monoclonal antibody in the directory that treats renal cancer, triple-negative breast cancer, and melanoma [1] - Junshida® is the first product to be included in the directory for patients intolerant to statins, marking it as the only domestic PCSK9-targeted drug in the new directory [1]

Core Insights - The National Healthcare Security Administration (NHSA) has officially announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and 19 drugs in the first version of the Commercial Health Insurance Innovative Drug Catalog, effective from January 1, 2026 [1][2][3] Industry Summary - The NHSA has adjusted the drug catalog for the eighth time since its establishment, with a total of 949 new drugs added over the years, and the medical insurance fund has spent over 4.6 trillion RMB on negotiated drugs, driving sales exceeding 6 trillion RMB [1][2] - The new catalog includes 50 first-class innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [3] - The inclusion of drugs for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions, addresses gaps in basic medical insurance coverage [2][3] Company-Specific Updates - Green Leaf Pharmaceutical has successfully included five new products in the NHSA's drug catalog, including MiMeiXin® and ZhanBiJia® [4] - Fuhong Hanlin announced that its product Fuzhuoning® has been included in the NHSA's drug catalog for specific indications [5] - Junshi Biosciences reported that its products Tuoyi® and Junshida® have been successfully included in the NHSA's drug catalog [6] - Innovent Biologics has successfully added seven innovative products to the new NHSA drug catalog, including Daboru® and Xindimian® [6]